Haematolymphoid Tumours Textbook 2026-2027: A Clinical Reference Covering Marrow Morphology, Immunophenotyping, and Molecular Classification for Diagnostic Pathology Residents

Hampton, MD, Jeremy D.

ISBN 13: 9798177650395

Edité par Independently published, 2026

A propos de cet article

Print on Demand.

N° de réf. du vendeur I-9798177650395

Détails bibliographiques

• Titre: Haematolymphoid Tumours Textbook 2026-2027: A Clinical Reference Covering Marrow Morphology, Immunophenotyping, and Molecular Classification for Diagnostic Pathology Residents
• Éditeur: Independently published
• Date de parution: 2026
• Langue: anglais
• ISBN à 13 chiffres: 9798177650395
• Reliure: Couverture souple
• État de l'article: New

A propos de ce titre

Synopsis

Know when the evidence is enough to sign the case out.

Hematolymphoid diagnosis carries the highest second-opinion discordance in surgical pathology, and the revisions cluster in one place: an entity named before the evidence converged. This textbook is organized around the fifth-edition World Health Organization framework and the integrated diagnosis it made standard, treating morphology, immunophenotype, genetics, and clinical context as four evidence streams whose definitional weight shifts entity by entity. Twenty-nine chapters carry pathology residents, hematopathology fellows, and surgical pathologists covering marrow and node work from specimen triage through the myeloid neoplasms, the mature B-cell and T-cell lymphomas, plasma cell disease, and the histiocytic tumors.

Every chapter states the configuration of findings at which a diagnosis becomes defensible and the look-alike that most often defeats it.

What this reference puts within reach at the microscope

• Specimen triage, fixation, and decalcification protocols that decide which ancillary studies still work — allocate limited tissue so the discriminating test survives

• Flow cytometric gating, hematogone discrimination, and residual disease reporting standards — separate regeneration from relapse without a second marrow

• Break-apart probe interpretation, variant allele frequency, and clonality testing limits — read a molecular report for what it excludes as well as what it shows

• Reactive nodal patterns, tumor-like lesions, and the in-situ neoplasias — recognize the benign mimics that account for most overcalls

• WHO-aligned criteria for acute leukemias, myelodysplastic and myeloproliferative neoplasms, and the overlap category — apply blast thresholds and defining lesions in order

• Grading, transformation assessment, and rearrangement testing across the B-cell lymphomas — direct the biopsy and the panel to the finding that changes therapy

• T-cell, NK-cell, cutaneous, and immunodeficiency-associated disease — reach the entities that hide in compartments routine staining never reveals

• The Master Convergence Point Index — 174 diagnostic thresholds cross-referenced by specimen, phenotype, genetic lesion, reasoning error, and mimic pair

Open it beside the scope and settle the case that will not resolve.